OVERVIEW

Choosing Glucose Lowering Therapies for Maximum Benefits in Type 2 Diabetes Mellitus (T2DM) is organized by Pri-Med and would be held during Dec 03, 2015 - Dec 03, 2016. The target audience for this medical event are basically for physicians. This CME conference has been approved with a maximum of 1.50 AMA PRA Category 1 Credits.

The new and emerging therapies include new insulin formulations and delivery, as well as new agents to use in combination have been developed allowing for a greater individualization of T2DM therapy. These have included concentrated and basal insulins and the growing presence of incretin based therapies. These new therapeutics are helpful in preventing post - prandial hyperglycemia often seen in T2DM.

Objectives :
• Select and optimize therapies for patients with T2DM.
• Integrate incretin therapies into strategies to improve glycemic control in patients with T2DM.
• Apply combination therapy using oral agents, incretin-based therapy, and new and emerging formulations of basal insulin to minimize glycemic variability.
• Devise therapeutic strategies for insulin resistant patients.

SPECIALITIES

Endocrinology, Metabolism and Diabetes

RELATED ONLINE COURSES